5KVD
Zika specific antibody, ZV-2, bound to ZIKA envelope DIII
Summary for 5KVD
Entry DOI | 10.2210/pdb5kvd/pdb |
Related | 5KVE 5KVF 5KVG |
Descriptor | Zika Envelope DIII, ZV-2 Antibody Fab Light Chain, ZV-2 Antibody Fab Heavy Chain, ... (7 entities in total) |
Functional Keywords | zika virus, envelope diii, viral protein, antibody, igg2c, structural genomics, center for structural genomics of infectious diseases, csgid., viral protein-immune system complex, viral protein/immune system |
Biological source | Zika virus (ZIKV) More |
Cellular location | Virion membrane ; Multi-pass membrane protein : A0A024B7W1 |
Total number of polymer chains | 3 |
Total formula weight | 60344.52 |
Authors | Zhao, H.,Nelson, C.A.,Fremont, D.H.,Center for Structural Genomics of Infectious Diseases (CSGID) (deposition date: 2016-07-14, release date: 2016-08-03, Last modification date: 2024-10-23) |
Primary citation | Zhao, H.,Fernandez, E.,Dowd, K.A.,Speer, S.D.,Platt, D.J.,Gorman, M.J.,Govero, J.,Nelson, C.A.,Pierson, T.C.,Diamond, M.S.,Fremont, D.H. Structural Basis of Zika Virus-Specific Antibody Protection. Cell, 166:1016-1027, 2016 Cited by PubMed Abstract: Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C' loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV. PubMed: 27475895DOI: 10.1016/j.cell.2016.07.020 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.65 Å) |
Structure validation
Download full validation report